Verve Therapeutics
Verve Therapeutics raises $213M Series C at $1B valuation
Verve Therapeutics: Series C Funding Round
Verve Therapeutics has successfully raised $213M in Series C funding, reaching a valuation of $1B.
Company Overview
Gene editing for heart disease
Funding Details
The Series C round was led by Foresite Capital, with participation from GV, F-Prime Capital, ARCH Venture Partners, Biomatics Capital.
Company Information
- Headquarters: 26 Landsdowne Street, Cambridge, MA 02139
- Founded: 2018
- Employees: 200+
- Category: Biotech
Investment
Verve Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Foresite Capital: Verified investor in Series C
- GV: Verified investor in Series C
- F-Prime Capital: Verified investor in Series C
- ARCH Venture Partners: Verified investor in Series C
- Biomatics Capital: Verified investor in Series C
Company Info
Investors (5)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free